Tumor venéreo transmissível canino com resistência quimioterápica e metástase esplênica - Relato de caso
Canine transmissible venereal tumor with chemotherapy resistance and splenic metastasis- Case report
DOI:
https://doi.org/10.15446/rfmvz.v66n3.84262Keywords:
TVTC, Cão, Metástase, Quimioterapia (es)TVTC, Dog, Metastasis, Chemotherapy (en)
TVTC, Cão, Metástase, Quimioterapia (pt)
Downloads
O Tumor Venéreo Transmissível Canino (TVTC) é uma neoplasia de células redondas que tem a particularidade de se implantar em mucosas que tenham perdido a sua integridade. Nesse local o tumor prolifera e ocasionalmente origina metástase. Em geral, o tumor responde ao tratamento com sulfato de vincristina, porém a resistência quimioterápica associada ao fenótipo tumoral tem sido documentada. Objetivou-se relatar um caso de TVTC genital de fenótipo citológico misto com metástase esplênica e o insucesso da quimioterapia com sulfato de vincristina, em uma fêmea canina, da raça Australian Cattle Dog, de cinco anos de idade. Após diagnóstico citológico e histológico, o tumor primário foi ainda caracterizado em fase de progressão e mostrou baixa expressão de moléculas do complexo principal de histocompatibilidade MHC (4,4 ± 2% classe I e 11 ± 4,1% classe II). A cadela foi submetida à ovariohisterectomia e esplenectomia terapêutica e não apresentou recidiva do tumor após 12 meses de acompanhamento clínico.
The canine transmissible venereal tumor is a type of round cell cancer that have the particularity of implanting in mucous tissue, when they lose their integrity, at which point the tumour proliferates and may even develop metastases. The tumor typically responds well to vincristine sulfate chemotherapy, although there are cases of resistance to the drug correlated with the tumoral phenotype. We describe herein a genital mixed TVTC case with metastases at spleen and failure at vincristine sulfate chemotherapeutic treatment in a five years old Australian Cattle Dog female. After the cytological, histological and cytogenetic diagnostic, the primary tumor was still characterized in progression phase and showed low major histocompatibility complex expression MHC (4,4 ± 2% class I e 11 ± 4,1% class II. The dog underwent therapeutic splenectomy and ovariohysterectomy and did not present tumor recurrence within 12 months of clinical follow-up.
References
Amaral AS, Gaspar LF, Bassini-Silva S, Rocha NS. 2004.Cytological diagnostic of transmissible venereal tumor in the Botucatu region, Brazil (descriptive study: 1994-2003). Rev. Port Ciên Vet. 99(551):167–71.
Amaral AVC, Oliveira RFO, Silva APSM, Baylão ML, Luz LC, Sant’Ana FLF. 2012.Tumor venéreo transmissível intra-ocular em cão: relato de caso. Vet. e zootec. 19(1):79-85.
Ballestero FH, Montoya FL, Yamatogi RS, Duzanski AP, Araújo JP, Oliveira RA, Rocha NS. 2018. Does the tumour microenvironment alter tumorigenesis and clinical response in transmissible venereal tumour in dogs.Vet Comp Oncol. 1–9.
Calvert CA, Leifer CE, MacEwen EG. 1982.Vincristine for treatment of transmissible venereal tumor in the dog. J Am Vet Med Assoc.181(2):163-4.
Chandler JP, Yang TJ.1981. Canine transmissible venereal sarcoma: distribution of T and B lymphocytes in blood, draining lymph nodes and tumors at different stages of growth. Bra J Cancer. 44(4):514-21.
Chikweto A, Kumthekar S, Larkin H, Keshaw CDP, Sharma TRN, Bhaiyat MI. 2013. Genital and Extragenital Canine Transmissible Venereal Tumor in Dogs in Grenada, West Indies. OJVM. 3(2): 111-4.
Chu RM, Lin CY, Liu CC, Yang SY, Hsiao YW, Hung SW, et al. 2001.Proliferation characteristics of canine transmissible venereal tumor. Anticancer Res. 21: 4017–24.
Dunn GP, Old LJ, Schreiber RD.2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity.21(2):137-48.
Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2):137-48.
Duzanski AP, Fêo HB, Montoya LM, Seullner CV, Rocha NS. 2017.Canine Transmissible Venereal Tumor: Is its biological behavior changing? Anat Rec (Hoboken). 300(6):1009-10.
Duzanski AP.2017. Interação entre hospedeiro e tumor venéreo transmissível canino: diversidade de células mononucleares e do complexo principal de histocompatibilidade [dissertação]. Botucatu (SP): Universidade Estadual Paulista.
Flórez LMM, Ballestero HF, Duzanski AP, Paulo RO. Bersano PRO, Lima JF, et al.2016. Immunocytochemical characterization of primary cell culture in canine transmissible venereal tumor. Pesq. Vet. Bras. 36(9):844-50.
Floréz LMM, Fêo HB, Silva GN, Yamatogi RS, Aguiar AJ, Araújo JP, Rocha NS. 2016.Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response.Vet Comp Oncol.
Flórez MM, Pedraza F, Grandi F, Rocha NS. 2012. Cytologic subtypes of canine transmissible venereal tumor. Vet Clin Pathol. 41(1):4-5.
Ganguly B, Das U, Das K.2016. Canine transmissible venereal tumour: a review. Vet Comp Onc.14(1):1–12.
Hantrakul S, Klangkaew N, Kunakornsawat S, Tansatit T, Poapolathep A, Kumagai S, Poapolathep S. 2014. Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). J Vet Med Sci.76(12):1549-53.
Horta RS, Viana AAS, Queiroz AT, Lavalle GE, Araujo MR, Araujo RB. 2012. Diagnostico diferencial entre sarcoma histiocítico e tumor venéreo transmissível com disseminação extragenital-relato de caso. Clínic vet. 98:96-102.
Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM. 2008.Interactions of host IL-6 and IFN-c and cancer-derived TGF-b1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother. 57:1091–1104.
Hsiao YW, Liao KW, Hung SW, Chu RM. 2002.Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol. 87(1-2):19–27.
Hsiao YW, Liao KW, Hung SW, Chu RM. 2004.Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-b1 and restores the lymphokine-activated killing activity. J Immunol. 172(3):1508–14.
Liao K, Hung S, Hsiao Y, Bennett M, Chu R.2003. Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically toxic for B cells. Vet Immunol Immunopathol. 92(3-4):149-62.
Lima CRO, Rabelo RE, Vulcani VAS, Furtado AP, Helrigel PA, Brito LAB, Moura VMBD .2013. Morphological patterns and malignancy criteria of transmissible venereal tumor in cytopathological and histopathological exams. Braz J Vet Res Anim Sci. 50(3):238-46.
Metzger MJ, Villalba A, Carballal MJ, Iglesias D, Sherry J, Reinisch C, Muttray AF, Baldwin SA, Goff SP. 2016.Widespread transmission of independent cancer lineages within multiple bivalve species. Nature.534(7609):705-9.
Mukaratirwa S, Chiwome T, Chitanga S, Bhebhe E. 2006.Canine transmissible venereal tummour: assessment of mast cell numbers as indicators of the growth phase. Vet Res Commun.30(6):613-21.
Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA.2006. Clonal origin and evolution of a transmissible cancer. Cell.126(3):477-87.
Paranzini CS, Sant’anna MC, Di Santis GW, Martins MIM. 2015. Prevalence of different cytomorphological types of transmissible venereal tumours and the association with prognosis in dogs treated with vincristine sulphate – Retrospective study. Semina: Ciênc Agr. (36):3795-3800.
Pérez J, Day MJ, Mozos E.1998. Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Vet Immunol Immunopathol. 64(2):133-47.
Rocha NS, Tremori TM, Carneiro JAM. 2014. Fine Needle Aspiration Cytology in the Diagnosis of Canine Cutaneous Transmissible Venereal Tumor— Case Report. OJVM. 4: 204-9.
Rogers KS.1997. Transmissible veneral tumor. Comp Cont Educ Pratc Vet. 19(9):1036-45.
Santos FGA, Vasconcelos AC, Nunes JES, Cassali GD, Paixão TA, Martins AS, et al.2008. Apoptosis in the transplanted canine transmissible venereal tumor during growth and regression phases. Arq. Bras. Med. Vet. Zootec.60(3):607-12.
Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR. 2010. Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract. 206(1):1-8.
Simermann NFS. Sulfato de vincristina no tratamento do tumor venéreo transmissível frente à caracterização citomorfológica. 2011. [Dissertação Mestrado em Medicina Veterinária]. [Goiânia, Brasil] Universidade Federal de Goiânia.
Sousa J, Saito V, Nardi AB, Rodaski S, Guérios SD, Bacila M. 2000. Características e incidência do tumor venéreo transmissível (TVT) em cães e eficiência da quimioterapia e outros tratamentos. Arch Vet Sci. 5:41-8.
Stockmann D, Ferrari HF, Andrade AL, Lopes RA, Cardoso TC, Luvizotto MCR. 2011. Canine transmissible venereal tumours: aspects related to programmed cell death. BJVP. 4:67-75.
Strakova A, Murchison EP.2014. The changing global distribution and prevalence of canine transmissible venereal tumour. BMC Vet Res.10:168.
Strakova A, Murchison EP. 2015.The cancer which survived: insights from the genome of an 11000 year-old cancer. Curr Opin Genet Dev.30:49-55.
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
CrossRef Cited-by
1. Anderson do Prado Duzanski, Luis Mauricio Montoya Flórez, Haline Ballestero Fêo, Graziela Gorete Romagnoli, Ramon Kaneno, Noeme Sousa Rocha. (2022). Cell-mediated immunity and expression of MHC class I and class II molecules in dogs naturally infected by canine transmissible venereal tumor: Is there complete spontaneous regression outside the experimental CTVT?. Research in Veterinary Science, 145, p.193. https://doi.org/10.1016/j.rvsc.2022.02.020.
Dimensions
PlumX
Article abstract page views
Downloads
License
Copyright (c) 2019 A. P. Duzanski, A. D. Ortiz, M. W. Fonseca, M. M. Flórez, L. T. Rodrigues, F. Michelon, N. S. Rocha

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
The authors retain copyright of their work and grant the journal the right of first publication.
Readers are free to copy and redistribute the material in any medium or format under the license terms, provided proper attribution is given, the work is not used for commercial purposes, and no modifications or derivatives are made.



